These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7561189)

  • 21. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines.
    Rimmelzwaan GF; Nieuwkoop N; Brandenburg A; Sutter G; Beyer WE; Maher D; Bates J; Osterhaus AD
    Vaccine; 2000 Dec; 19(9-10):1180-7. PubMed ID: 11137255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to influenza vaccine in people with non-protective HI antibody titers.
    Baldo V; Baldovin T; Floreani A; Minuzzo M; Trivello R
    Eur J Epidemiol; 2006; 21(11):843-5. PubMed ID: 17082899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.
    Yang J; Shim SM; Nguyen TQ; Kim EH; Kim K; Lim YT; Sung MH; Webby R; Poo H
    Sci Rep; 2017 Mar; 7():44839. PubMed ID: 28322289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine.
    Iinuma H; Nerome K; Yoshioka Y; Okinaga K
    Scand J Immunol; 1995 Jan; 41(1):1-10. PubMed ID: 7824883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.
    Kawano M; Morikawa K; Suda T; Ohno N; Matsushita S; Akatsuka T; Handa H; Matsui M
    Virology; 2014 Jan; 448():159-67. PubMed ID: 24314646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.
    Chawansuntati K; Chotirosniramit N; Sugandhavesa P; Aurpibul L; Thetket S; Kosashunhanan N; Supindham T; Kaewthip O; Sroysuwan P; Sirisanthana T; Suparatpinyo K; Wipasa J
    Hum Vaccin Immunother; 2015; 11(9):2253-65. PubMed ID: 26091502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a universal CTL-based vaccine for influenza.
    Cargnelutti DE; Sánchez MV; Mattion NM; Scodeller EA
    Bioengineered; 2013; 4(6):374-8. PubMed ID: 23337287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines.
    Ennis FA; Rook AH; Qi YH; Schild GC; Riley D; Pratt R; Potter CW
    Lancet; 1981 Oct; 2(8252):887-91. PubMed ID: 6117682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.
    Deliyannis G; Jackson DC; Ede NJ; Zeng W; Hourdakis I; Sakabetis E; Brown LE
    J Virol; 2002 May; 76(9):4212-21. PubMed ID: 11932386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.
    Bolton KJ; McCaw JM; Brown L; Jackson D; Kedzierska K; McVernon J
    PLoS One; 2015; 10(3):e0120138. PubMed ID: 25811654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
    Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
    Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.